In the AFFIRM trial, androgen receptor antagonist therapy with enzalutamide improved the overall survival of men with metastatic castration-resistant prostate cancer (mCRPC) with disease progression after docetaxel treatment, compared with placebo. A new analysis of the secondary end points of this trial has revealed that the therapeutic benefit of enzalutamide extended to patient wellbeing and function outcomes. The improvements in these domains included a significantly greater incidence of overall improvement in health-related quality of life (HRQoL) compared with placebo (42% versus 15%; P <0.0001), as well as delayed time to HRQoL deterioration (median 9.0 months versus 3.7 months; P <0.0001). Median time to first skeletal-related event and various pain outcomes were also all markedly improved in the enzalutamide group.